This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
TheStreet Rating

10 Best Healthcare Equipment Stocks for 2014

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks. These 10 healthcare equipment stocks are rated highest by TheStreet Ratings' value-focused stock rating model.

Equity Top: Healthcare Equipment

Source: TheStreet Ratings

Best Investments for 2014

Healthcare Equipment

Biotech columnist Adam Feuerstein answers readers' questions about health care.
10/17/14 7:05AM
Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.
8/13/14 12:04PM
For all the hype about Afrezza's greatness, Mann walks away with a joint venture in which he secures just one-third of Afrezza's potential profit -- and losses.
8/11/14 6:49AM
AcelRx believes it can gather all the requested information and re-submit Zalviso to the FDA before the end of the year.
7/28/14 9:44AM
MannKind must report second-quarter financials before the end of the second week in August, which sets a quasi-deadline for Afrezza partner plans.
7/25/14 11:30AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
7/18/14 7:51AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
7/14/14 9:30AM
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
7/10/14 11:54AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
6/20/14 8:03AM
Let's wind back the tape more than 9 years to documents the many instances in which MannKind executives made promises about partnering the inhaled insulin Afrezza.
6/17/14 2:25PM
EnteroMedics and its VBLOC "fat-zapping" implantable medical device will be the focus of an FDA advisory panel meeting next Tuesday, June 17. If FDA follows historical form, the agency's review of VBLOC's safety and efficacy will be available publicly tomorrow morning.
6/12/14 8:00AM
Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.
4/10/14 11:52AM
TheStreet's Adam Feuerstein sets the table for Mannkind and its inhaled, rapid-acting insulin Afrezza ahead of Tuesday's FDA advisory panel meeting.
3/31/14 7:56AM
When your job is helping MannKind sell stock, it's not hard to be a bull.
3/18/14 3:22PM
A preview of the April 1 FDA advisory panel convened to review MannKind's inhaled insulin device.
3/6/14 10:14AM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs